Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 …
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 …
Oxford-based company Genomics is launching its Health Insights test across the UK, which will be used to predict and prevent …
Cell and gene therapies represent a groundbreaking advancement in medical science, offering transformative opportunities for treating complex and previously untreatable …
Clarametyx Biosciences has received approval from the Independent Data Monitoring Committee (DMC) to progress its Phase Ib/IIa trial of CMTX-101, an …
The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase II/III …
The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase II/III …
At the 2025 European Hematology Association (EHA) Congress, held from June 12 to June 15 in Milan, Italy, updated results …
According to the World Health Organization, endometriosis affects approximately one in ten women and girls of reproductive age globally. There …
A recent publication by the US Centers for Disease Control and Prevention (CDC) reports the trends of birth by gestational …
The UK Government has announced its 10-Year Health Plan to expedite clinical trials and transform patient care with new treatments. The …
Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of monoclonal antibody inhibitor of plasma kallikrein, navenibart …
Relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) continues to present significant treatment challenges, particularly for patients who are …
At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 to 15 June, the preliminary results …
Serepta and global partner Roche have discontinued the commercial and clinical use of Duchenne muscular dystrophy (DMD) gene therapy Elevidys …
Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey (talquetamab-tgvs) and Tecvayli (teclistamab-cqyv) …